Introduction to ARIA
ARIA Reporting Templates
Clinical reporting of ARIA should follow a structured report. Here are template reports for baseline scan and monitoring scans, co-developed with the ESNR and the EAN:
Baseline
Monitoring
Recommended Literature
Considerations for patients with preexisting cerebrovascular disease
Greenberg, S. M., Aparicio, H. J., Furie, K. L., Goyal, M. S., Hinman, J. D., Kozberg, M., Leonard, A., & Fisher, M. J. (2025). Vascular Neurology Considerations for Antiamyloid Immunotherapy: A Science Advisory From the American Heart Association. Stroke, 56(1). https://doi.org/10.1161/STR.0000000000000480
“Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics” Brain. 2023 Jun 6;146(11):4414–4424. doi: 10.1093/brain/awad188
ASNR resources https://www.asnr.org/education-resources/alzheimers-webinar-series/
“Alzheimer Disease Anti-Amyloid Immunotherapies: Imaging Recommendations and Practice Considerations for Monitoring of Amyloid-Related Imaging Abnormalities” AJNR Am J Neuroradiol. 2025 Jan 8;46(1):24-32. DOI: 10.3174/ajnr.A8469
Comparing ARIA‐E severity scales and effects of treatment management thresholds
Alzheimers Dement 2022;14:e12376. doi: 10.1002/dad2.12376
Oliveira TG, Vernooij MW, Frisoni GB, Wiest R, Barkhof F. Are we ready for amyloid-related imaging abnormalities (ARIA) monitoring? A European survey among neuroradiologists and neurologists by the ESNR/EAN Working Group. Eur Radiol. 2026 Jun;36(6):4774-4787. doi: 10.1007/s00330-025-12214-8. Epub 2026 Jan 6. PMID: 41493545.
Appropriate use recommendations
Cummings, J., Apostolova, L., Rabinovici, G. D., Atri, A., Aisen, P., Greenberg, S., Hendrix, S., Selkoe, D., Weiner, M., Petersen, R. C., & Salloway, S. (2023). Lecanemab: Appropriate Use Recommendations. The Journal of Prevention of Alzheimer’s Disease, 10(3), 362–377. link
Rabinovici, G. D., Selkoe, D. J., Schindler, S. E., Aisen, P., Apostolova, L. G., Atri, A., Greenberg, S. M., Hendrix, S. B., Petersen, R. C., Weiner, M., Salloway, S., & Cummings, J. (2025). Donanemab: Appropriate use recommendations. The Journal of Prevention of Alzheimer’s Disease, 12(5), 100150. link
Park, K. H., Kim, G. H., Kim, C.-H., Koh, S.-H., Moon, S. Y., Park, Y. H., Seo, S. W., Yoon, B., Lim, J.-S., Kim, B. C., Kim, H.-J., Na, H. R., Shim, Y., Yang, Y., Lee, C.-N., Rhee, H. Y., Jung, S., Jeong, J. H., Choi, H., … Choi, S. H. (2024). Lecanemab: Appropriate Use Recommendations by Korean Dementia Association. Dementia and Neurocognitive Disorders, 23(4), 165. link
Mummery CJ, Rasmussen J, Blackburn D, Coulthard E, Davies RR, Dorsey R, Fox NC, Hosseini AA, Ivenso C, Jones M, Kennelly SP, Kipps C, Lashley D, Mackay G, Negi R, Nilforooshan R, Passmore PA, Perry R, Raymont V, Rowe JB, Russ TC, Taylor JP, Burns A. Lecanemab appropriate use recommendations for clinical practice in the UK. J Neurol Neurosurg Psychiatry. 2026 Apr 15;97(5):372-384. doi: 10.1136/jnnp-2025-336597. PMID: 41390238; PMCID: PMC13151530. link